CDKN2A expression showed a strong correlation with the immune checkpoint molecules PDCD1, CD274, and CTLA4, so we hypothesized that ICIs might be effective in CRC patients with high CDKN2A expression. Here, CDKN2A is linked to colorectal carcinoma.